Brief: Bone Therapeutics Introduces Interim Analysis In Phase IIB Tibial Fractures Study

Biosenic SA

15/07/2022 06:07

July 15 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * BONE THERAPEUTICS OPTIMIZES STATISTICAL ANALYSIS AND
INTRODUCES
INTERIM ANALYSIS IN THE ONGOING ALLOB PHASE IIB STUDY FOR
HIGH-RISK TIBIAL FRACTURES
    * IMPLEMENTATION OF AN INTERIM ANALYSIS FOR ONGOING PHASE
IIB
CLINICAL TRIAL WITH ITS ALLOGENEIC BONE CELL THERAPY PRODUCT,
ALLOB
    * CURRENT OPERATIONAL FOCUS OF BONE THERAPEUTICS ON CONDUCT
OF
STUDY AIMS AT ENSURING DELIVERY OF TOP LINE DATA AS SCHEDULED BY
OF FIRST HALF OF 2023
    * BONE THERAPEUTICS WILL PROCEED IN NEAR TERM WITH
SUBMISSION OF
AMENDMENTS TO STUDY PROTOCOL FOR APPROVAL TO REGULATORY
AUTHORITIES
    * SHOULD PANDEMIC CONTINUE TO HAVE IMPACT ON PATIENT
AVAILABILITY,
BONE THERAPEUTICS MAY HAVE TO RE-EVALUATE THIS TIMELINE AND, IN
THAT EVENTUALITY, WILL COMMUNICATE AGAIN TO MARKET

Source text for Eikon:  ID:nGNE7mK4v0 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))